Unlocking Potential: Hidden Data and Disparities in Clinical Trial Participation
36 minAudio
Join host Jonathan Kaskey in this thought-provoking episode of Pharma Sessions as he invites special guest Denise Bronner, Director of Clinical Trial Diversity and Inclusion at Janssen, to delve into critical issues facing the pharmaceutical industry. Together, they explore the challenges of data sharing, the underrepresentation of non-white individuals in clinical trials, and the need for more inclusive physician training. Top 5 learnings from the episode: The critical need for data shar... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_03DEI or diversity has been seen for the longest time as a challenge.
SPEAKER_01Right.
SPEAKER_03But I have always been pushing for the narrative that it should be seen as an opportunity. And when you think about the fact that you can tap into new patient pools, that's more data that can inform your science. That is a larger patient pool for patients to be recruited from to speed up your timelines. That is an opportunity for new customers to sustain your portfolio. Like those are business opportunities.
SPEAKER_00Hello, hello. Welcome back to Pharma Sessions. This is the final episode of season one. I'm taking a break for the summer and we'll be back in the fall. In today's episode, I speak with Dr. Denise Bronner. Denise is the director of diversity and inclusion in clinical trials for Janssen and also an angel investor. This is actually the third in my series of podcasts on clinical trial diversity. I'm really happy with how these episodes complement each other.
SPEAKER_00The first was with Camille Pope, who serves on the consulting side, followed by Renata Jones, doing the hard work at a grassroots level. Having Denise share about making change from within large pharma provides a third and necessary perspective. So if you like this conversation, go check out those others. Throughout our interview, Denise shares her observations from her time in consulting and work at Jansen. Here are the top five things you'll learn from this frankly eye-opening conversation.
SPEAKER_00First, the critical need for data sharing in the pharma industry and how it can foster innovation. Second, the concerning lack of representation of non white people in clinical trials and the reasons behind this disconnect. Third, the importance of analyzing claims data and site specific data to uncover the underlying issues affecting patient enrollment in clinical trials. Fourth, the crucial role of healthcare access, implicit bias, and community engagement in empowering underrepresented populations.
SPEAKER_00And finally, the steps being taken by pharmaceutical companies and society to drive diversity, equity, and inclusion in healthcare. With the usual disclaimers, the views and opinions here are mine and Denise's and don't reflect those of our employers. Get ready to be inspired and enlightened, and let's dive right in.
SPEAKER_03So I am an academic at heart. I started off with doing a PhD, and I consider myself to be a former scientist who turned to the dark side. I always had a love for business and getting into industry and made that jump after doing an academic postdoc for a little bit, getting into consulting and did a bit of getting into big pharma where I'm at currently.
SPEAKER_00What was your PhD in?
SPEAKER_03Oh, my PhD is in microbiology and immunology.
SPEAKER_00Oh, great.
SPEAKER_03Yeah, and I have to say, at the heart of everything that I've done, data has always been something that's really been a strong interest of mine's, in addition to science. Data, I think, is really cool because you can tell really cool stories with it. You get to identify trends and things that are hidden in the data itself. But during my time in academic research and consulting and big pharma, I've started to realize that there's a hidden story within data. That there is things that are happening that are giving a little bit of information about where patients are or which patients are missing.
SPEAKER_03And I've always wanted to question what are the gaps, what are we not really seeing here? And really thinking about ways to develop a compelling story. And when we look into anything, especially within pharma, and looking really at historical clinical trials, you start to see that there are a lot of patients that are not seen in the data. And we know that we have our cultures, different cultures, different backgrounds, different types of people. And yet a lot of them are not in that clinical research, and we're missing on understanding how disease progressed within them or the efficacy of our therapies and diagnostics.
SPEAKER_03So for me, my background really has been driven by this idea of science and trying to understand what are we missing and how can I as a person really fill that in?
SPEAKER_00Yeah, that's really interesting. And then it sounds like also the impact, right? Here we're talking about healthcare space, but I'd imagine there's all sorts of impacts of either recognizing or not recognizing that your data is incomplete or missing certain pieces. Was I'm just curious, was there anything in particular, was there an aha moment for you where you that start started you thinking about this idea of hidden data?
SPEAKER_03Oh, I think really it was really interesting when I was in consulting. And it started there when we were looking at understanding feasibility programs across different pharmacompanies. And you start to see how industries or different companies are really siloed, and that there's a lot of data that they could have been sharing with each other on best practices or lessons learned that was not really being shared because of this idea about competitive edge, right? It started there, and I think that was really interesting to hear how there were certain things that some companies had tried that others were just starting, and they're like, we did that, and this is what we came across.
SPEAKER_03And it was like that ability to cross-pollinate with each other without the fear of, oh, you're gonna have a competitive edge on me. I thought was very interesting. And then when I made that transition to where I am today at Janssen and really start to look into historical data about who is being represented in our clinical trials, you really start to see that when you think about the US population as a whole, we're starting to see more and more non-whites, their population size has grown significantly over the past few decades. And yet when you look in clinical trials, they're barely, if you include everyone, black, Hispanic, Asian, Native American, Native Alaskan, all under one umbrella as a group as non-white, that they're only representing maybe 15% of clinical trial participants.
SPEAKER_03And you think about the thousands of trials that are going on, and you go, well, why is that? Why is there such a disconnect when we look at the population and it's not reflected in our data?
SPEAKER_00And then if you're not even denoting who people are with a little bit more specificity, you can't go backwards and search for things, right? The data itself becomes flawed. It's interesting. So this is the third conversation that we've done on this podcast around the DEI clinical space. And in the first one, it was with a woman named Camille Pope who works for Acclinate, which is one of those, it's a consultancy agency. And one of the things I've always thought was interesting about the consultancy side is like you do actually get to see how maybe five, fifteen different companies are trying to solve for these things.
SPEAKER_00Whereas if you're at a very big company, it can be easy to think that the world strategy ends at the walls of the company. So there's definitely opportunities to bring people together. So I'm just curious, like along those lines, what are traditional sources of data and why might they be lacking?
SPEAKER_03Oh man. So I talked a little bit about this in an article that I have on my LinkedIn newsletter, The Pulse. And really what we're starting to see is the use of claims data sets very heavily. And you can also look at population data with prevalence and incidents, you can look at historical trial recruitment data, and you can also get into qualitative data sets as well, looking at patient and site voice. And the interesting thing about it when you look at these types of data sets, sure, they're they have information by different demographics.
SPEAKER_03So you can look at sex assigned at birth, right? You can look at race, ethnicity, age, you can even go by geographies. But what you start to notice is that it's there's a low amount of diversity within those data sets as well. Because if you look at historical recruitment data, we know that there's in the FDA had put out a mandate and requirements now to have representation because a lot of studies were hitting 85-90% white. And these are in diseases where we know for a fact these diseases do affect people who are non-white.
SPEAKER_03But then you also start to look at claims data, and this is really based off of when a person goes to see a doctor, that billing code that gets added on there, this is how they can flag that, right? It's based off of disease and the type of test or therapy that they have been given, right? And what you start to notice is that because of healthcare access, that data too is also skewed in one way versus the other. And so we're starting to see that a lot of the data sources that we want to use, you really can't get gleam true insights from it because some people, some patients are not in that data.
SPEAKER_03And when you have patients that are being misdiagnosed, who are being dismissed by physicians, or because of the cost to go see a doctor or to get a certain type of drug, that data is not being reflected of the real population. And prevalence and incidence data now is starting to be more robust, but some of these data sets are really limited just to the US. Because if you look into other countries, especially like in Europe, there's a lot of privacy laws. So if you're able to try and gather a little bit more information on the demographics of patients, it's difficult to do.
SPEAKER_03So you're very limited in scope. And so you have to say to yourself, how can we leverage this data in a way to really identify where these patients are at? And this is where what work like with Acclinate is doing, we're really getting into the communities and what patient advocacy groups are doing, helps to raise the stakes and a little bit more of awareness of where these potential patients could reside.
SPEAKER_00Yeah. Well, there's a lot there. So maybe if we could just go back, one of the stories that was shared earlier was about actually forget the disease, but it was something that was prevalent in African Americans, not but it's situation exactly like what you described where the clinical trial was 85% white, and the person was talking about going and meeting with a patient advocacy group and the advocacy saying, How come there's nobody in here that looks like me? And it's it seems the more that I'm talking to people about this, the more I don't know if intersectional is the right word, but it's like it all come, it all cycles on each other.
SPEAKER_00You have a bad experience with a healthcare system, you're not believed, you don't have access, you don't have a provider, you don't have insurance, and then there's this mistrust, and so and then you're gonna try what a lot of people are considering like experimental, right? You're gonna be in a clinical trial for something that's not approved? I don't think so. And so there's this whole uphill, uphill battle where it to me it seems really difficult to segment, separate those things one from another. So when you're thinking about addressing that, are you taking off point solutions where it's like, hey, we can make an impact here through education, or we can make an impact here through an access program, or are you trying to operate a little bit more holistically and saying there's like systemic issues that need to be addressed?
SPEAKER_03I think honestly, what has happened historically is very poignant. The biggest thing that I'm getting that I think we we need to think about here is it needs to be enduring and it needs to be holistic because you can raise awareness and that's great. You've empowered the patient. They know about the disease, they know about the different avenues, but when they go to these areas and they go to the medical field, they go to a doctor, and the doctor dismisses them because in their minds they're thinking you don't have this disease because you're black.
SPEAKER_03This has happened a lot with people who have IBD, right? They're black or Hispanic and they're being told you can't have it because you're black or Hispanic. So when you're meeting that part initially, and it takes you a while to finally find a doctor, but the doctor's out of network, or the doctor's two hours away. These are all the things that are piling up onto a patient that as much as we like to talk to the patient and be very much focused on well, we need to empower the patient, there are things that are happening that are outside of them that we really need to focus on.
SPEAKER_03Like, are we training physicians to identify and to combat implicit bias? Are we partnering with the right physicians, even though we may have heard from patients or have had interactions with these physicians and they're like, no, I don't see a need for this, or I don't understand this. Are we partnering with the right physicians, right? Are we willing to partner with the physician that may not have the clinical research experience but is heavily invested in their patients, who has the patient demographics that we're looking for, and who understands the importance of not only educating and raising awareness, but trying to find those opportunities for their patients in the right way?
SPEAKER_03Those are things that we can do on our end. And when you start to get into other areas of healthcare access, thinking about cost, thinking about how and where we're gonna be launching some of our therapies or trials, right? Thinking about ways of investing in the community. So not just setting up shop when we have a study, are we actually going to be there before the study, during the study, and after the study to maintain that level of engagement with the site, with that community? And this is something that Aquilade and others like them have really pushed because you need to have that continuous engagement with the community.
SPEAKER_03Because again, it can feel very transactional, right? If you're not empowering them in a way where they can take this and it can grow within a and within that community, then you're really continuing to do the same historical things that have happened in the past, where you come in, you get what you need, and you leave.
SPEAKER_00And so get on the idea of hidden data, is there ever is there ever some type of a, I don't know what the right term is, negative analysis where it's like, hey, you have a hundred black patients and you nobody's been diagnosed with IBD in your practice, and that's in, I don't know what the actual number is, but that's abnormal, right? So that can't, that probably is statistically very unlikely. You should re-examine how you're treating people or what you're looking for with all with the EMRs and with all with claims data and with everything. Are people taking it to that point of saying, like, yeah, this is something that particular doctors at particular offices should be looking at?
SPEAKER_03Yeah, and so there probably are some individual physicians or at least groups that are starting to look into that. I know at least that at in my job, we're looking at it as if we know that there are sites based off of claims data and looking at just the demographics of patients at that site, as we're as the study is ongoing and we see screening and randomizations or enrollment numbers, and we're like, hey, there's a disconnect because you said during feasibility, you have these types of patients.
SPEAKER_03We look at the claims data within your community, and even at some of the data that's at your site, there should be these types of patients. So what's happening here? And it could be as you start to dig through that data, maybe they are screening these patients, but they're not being randomized. And that comes down to is it the protocol? Right? Is there something about our protocol that's very restrictive, right? And do we need to widen the funnel? Or is it something along the lines where they're seeing not only low randomized patients, but also low screenings? And you can say what's happening?
SPEAKER_03Are patients just not interested? Are you even having a conversation with these patients? That's where you start to dig into that type of data to try and understand from the site's perspective what is happening. And that's when you can use that data in a way to figure out what is that hidden story, and if it is something that can be mitigated, how can we go about doing that?
SPEAKER_00This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams instance into the perfect advisory board platform. Save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. That's really fascinating. So you're actually looking at it for individual protocols and you because you're making site decisions based on some assumed. And if you're not achieving those outcomes, then you're going back and you're re-examining why not.
SPEAKER_03You have to because each site is different, right? It's not a same cut cookie-cutter type of thing. And there are going to be sites that are in areas where there are opportunities. And for some that aren't, you can't really put them on the same level, right? It's it's going to do a disservice to that site. But for the sites that are in these areas where there's opportunities, are we doing everything that we can to empower them and to provide those opportunities to those patients in that area?
SPEAKER_00Yeah. It's so interesting because I've been working in the space on the vendor side for a while. And there were a number of years where you'd go, people would be, I'd be trying to help people recruit patients, and we'd be trying to fill it. And basically it was like, what's the cost per patient? And that was it. And now it's this interesting, it seems like there must have been an inflection point maybe a year ago, two years ago, three years ago, somewhere in that time frame, not that far ago, where now people are like, hey, this is an initiative, but now we have budget.
SPEAKER_00Yes. And I feel like that's a big difference. So I'm just curious, do you see this? Probably, I'm sure the FDA guidance is a major impetus, right? But what do you think that is where companies are really prioritizing this now?
SPEAKER_03I think it's because it's it's more of a push from society, right? The FDA has made it where now it's written into law, right? We have mandates now, updated guidances, but it's also the people. I think people now are way more vocal. Uh social media has allowed people to create communities, it has allowed them to have a platform to express their concerns. Medical TikTok has taken off, right? So people are going to these spaces to try and learn more. Some it's good information and some not so much. But I do think that society is now putting the onus on industry, medical pharma, to really step up.
SPEAKER_03Because if you are going to be selling these types of therapies and drugs or providing these types of diagnostics and preventative measures, we need to be seen. And I think there's a major push within society as a whole for representation. We're seeing this for representation in higher levels of the corporate ladder, for even on the side of like startups and investments, things along those lines, we're starting to see that education, right? Government. So with the fact that you now have people saying, hey, why am I not included? Why isn't there data to inform me if this is going to work for me?
SPEAKER_03I think we're now starting to see that, hey, either you catch up, right? You try to push forward with this, or you're going to get it left behind. And so you're starting to see this across the industry where a lot of the pharmaceutical companies now have DEI focused or GNOs, they're putting money into certain initiatives. And Jansen and Jay have really done a great job with putting in their our race of health equity, right? Where they have actually said, we're going to put money into this. We're going to not only think about this in terms of raising awareness and educating, but also thinking about the clinical trial space, how do we improve representation?
SPEAKER_03And that's this is just something that has really been pushed through to really change the game. And I think it's now being viewed as DEI or diversity has been seen for the longest time as a challenge.
SPEAKER_01Right.
SPEAKER_03But I have always been pushing for the narrative that it should be seen as an opportunity. And when you think about the fact that you can tap into new patient pools, that's more data that can inform your science. That is a larger patient pool for patients to be recruited from to speed up your timelines. That is an opportunity for new customers to sustain your portfolio. Like those are business opportunities, right? The the financial impact that can happen on that is substantial. And when you start to view it in that way, where you can actually revolutionize science and business, I think that's when you start to see the wheels really start to take off.
SPEAKER_03So it's not a challenge, it's more of an opportunity.
SPEAKER_00I love that framing of it's a societal pressure, but then also it's good for the science and it's good for the company. And if you happen to be in the market of providing IBD medications, wouldn't it be good to properly diagnose people? But then there's this mistrust issue, right? And mistrust of the healthcare system amongst black and Hispanic populations, for example, it's often discussed in historical terms. How does this perspective affect pharma's ability to effectively engage these communities?
SPEAKER_03Oh man, every time I hear mistrust, I always make this face.
SPEAKER_00And it's always because it's always put in a because this is an audio medium, right? That was a question.
SPEAKER_03I make a face. I like I make this like a face because it's always put in a historical sense. And it's important to highlight the historical atrocities that have happened, right? We think about Henrietta Lacks, we think about Tuskegee, the father of gynecology, the birth control uh study that they did in Puerto Rico, those things happen. We cannot gloss over that. But I think the biggest thing, especially when you talk to anyone who identifies as a person of color, is that there are still injustices that are happening to this day.
SPEAKER_03And when you look at some of these statistics, and and I'm gonna rattle off a couple, where there was a study that found that seven out of ten black people felt that they were being treated unfairly by the healthcare system. You have other studies that have talked about black patients being dismissed or undertreated for their pain. When you think about the trans community, 29% felt as though, or have stated, I should say not felt, but stated, that their healthcare provider refused to treat them because of their perceived gender identity, right?
SPEAKER_03And when you think about the latest story of Tori Bowie, who was the Olympian who just died of pregnancy complications, right? This is something that happens a lot. And black mothers are two to three times more likely to die than their white counterparts. And people will say, oh, maybe it's because of healthcare access. No, this is even if a woman is of higher socioeconomic status and educated. So when you think about these things that are consistently happening in the current time, right, these are traumas and dismissals that are happening to today.
SPEAKER_03And even with raising awareness about Henrietta Lax and Tuskegee, we're still seeing these issues, right? And there's a lot of bias that's in the system, right? And we when we hear about that, I think that's the piece that for me, we have to think about how do we engage better with these communities? How do we you can't sit here and gloss over it? You have to say this has happened, and we know these things are still happening. But here's what we're doing to improve your chances, to allow for your access to not be hindered, right?
SPEAKER_03For you to not have to go in and worry about, am I going to experience trauma or dismissal today? Right? Will I have to go in and fight to get a standard of care? And that is something that I think we need to do better with listening and really saying that is that's not should not go on the patient. That needs to go into the physicians, that needs to go in the industry to change how that's happening and to stop that from happening.
SPEAKER_00Yeah. Yeah, it's really it's almost in some ways easier to look at it in historical terms because then it's not something that happened. But and you could, I guess maybe it's you could draw a line and say, okay, the father of gynecology with his horrific experiments saying essentially black people slaves don't feel pain, right? And then to with the stat that you just you know you just rolled off, but at a certain point it's okay, striking everything, everything else out. Like the story, the Olympian is horrific. Like the story that's always struck with me is Serena Williams, who has more resources and any podcast.
SPEAKER_00All right, and she she almost died in pregnancy because she wasn't ready, because she said something is happening and she wasn't believed. So it is uh yeah, it's really, I feel like it's super important to talk about it in current terms because that is where you can take action and make an impact. And I'm just wondering like how aware are underserved communities of these issues, and how can pharma do a good job listening as well as talking, or what resources can industry people use to have intentional engagement with communities of color?
SPEAKER_03Yeah, I would say communities of color and underserved communities are painfully aware. They're they're living it, it's their day-to-day. And you have to make sure you're not talking to them as if they don't know what's going on. And I also think, too, you can't come off dismissive. And I will say that we have done some exercises within the industry and at my company where we've gone and done patient voice, we've talked, we've listened. But a lot of times we hear from patients and even from sites that's great that you've asked me this question and you guys have taken all this information, but we haven't seen anything being actually implemented.
SPEAKER_03What are you guys doing? So I think the biggest piece is a lot of times we think that, oh, with the advent of technology, we'll just throw a bunch of technology at patients and they'll love it. And the number one thing we kept hearing from patients is we just want better communication. When you're going in and talking to these communities, you're listening to them, you're providing them the information, telling them where the resources are. In addition, you're also saying that what we hear from you, we have incorporated that into our studies. We're partnering with site to have weekend hours because we know that your job, you may not have flexibility with that.
SPEAKER_03Or we've heard you and we've tried to create therapies where we wouldn't have as many visits to the site, right? Or we've provided extra materials and reminders for you to know what you should expect and why we're taking these samples, right? We are communicating back to patients throughout the study. Here's how the study is progressing. And the biggest thing too is when a study is completed, what came of it? Did the drug become available? What did the data say, right? And that's something that I think as an industry we need to do much better with.
SPEAKER_03We're not communicating back, right? We need to show them that they're not just a data point, but they're actually advancing science and that this is something that can really help society as a whole by treating some of these diseases that we're facing with in society. And the biggest thing is being very intentional, right? That it's enduring, it's intentional, right? And that you're always having that feedback of communication. And I think anything else tied to that, like you said earlier, budget. You've got to put money towards it. You can't just expect, we set up the site, yeah, but what else did you do?
SPEAKER_03Did you really engage? Did you put money into it? No? Of course. What do you think was gonna happen? It's not gonna be magic. So I think that's where we start to see. Are you really evaluating what you're doing? Are you tracking metrics to see what the impact is? Are you actually, before you do anything, actually getting feedback from people who you're gonna be pitching this to to say, yeah, that's not a good idea, or yes, this would be something that's good. So that's where I think you can start to see that you're being very intentional about what you're doing within these communities.
SPEAKER_00Yeah, it's well, it's really interesting, right? Because it's a lot of that is being respectful of people, right? Like you're giving me your time, you're giving, you're participating in this. And the benefit to the company happens then, or a lot of it, and but it is respectful to close the loop and to come into that. And especially the stat that you had listed earlier, dropped my jaw was the seven of ten black people saying they've been treated unfairly by the health system. That's a that's a big hill to overcome, right?
SPEAKER_00And so communication makes a lot of sense to me as a way to say, we're gonna treat you very we're treating you fairly in this experience, right? And part of that is telling you what we're doing, what we're taking off, asking, maybe asking your opinion a second time, and just the same way you would with the just having a respectful engagement seems really important.
SPEAKER_03Yeah, and that's and I think that's the biggest part too, is like I was saying earlier with physicians, are you choosing the right physician? Are we training them and raising their awareness and needs, right, on competency on how to engage with these types of patients? Because, like I said, a lot of times it's focused on the patient with engagement and raising their awareness and education, but the same has to happen with physicians as well. Because what I thought was very interesting is that there was a statistic when we're talking about within dermatology, like 49% of dermatologists and dermatology residents felt they were not adequately uh prepared and educated and trained on what these different types of diseases within dermatology look like on skin of color.
SPEAKER_03That's a large number. And right when you think about what tools and training that they have with the images, it's always on white skin. Not saying that it doesn't happen, but there are other people with different skin tones who are also suffering from psoriasis or atopic dermatitis. So, what are we doing to fill in that gap, to make it where they feel comfortable uh with being able to accurately diagnose these diseases? So that's something that we can do that's separate from patients, right? That's something that's really focused in on the physicians on what we can do so that when they're engaging with patients, regardless if it's a trial or not, they're doing this properly.
SPEAKER_00Interesting. So is it are you talking about things like CME or what are the programs that you're referring to?
SPEAKER_03Yeah, so you can do that through CME, you can do that through even like with site training with like our clinical trials, there's certain trainings that they have to go through. Could we put these type of cultural competency type of training there, right? Could we give other types of optional trainings for them to say, hey, here's a to raise your awareness about this? Or when we're doing these different types of events that we can put together to raise awareness and say, here's what we've learned, here's new data, right? Here's what we can put out there for these physicians. Um, or partnering with like companies like Visual DX, who has collected all these images and say, is there a way for us to create training materials uh for physicians?
SPEAKER_03Things along those lines that we can do that are not putting the onus on the patient, but more back onto the physicians who are sometimes one of the biggest barriers of healthcare access.
SPEAKER_00That's very interesting. So, as we wrap up here, what are you most excited or hopeful about to see happening in the space now? And how is that going to change the landscape over the next few years?
SPEAKER_03I have to say I'm very excited about the fact that society as a whole is really taking their health care seriously and that they are taking ownership of that, that they feel empowered to be able to do that. I'm also very excited about the fact that the FDA is really starting to put their foot down to say we're mandating and putting out requirements and guidances on these things here for improving representation. And I love the fact that we're starting to see more and more people like myself who are moving into these spaces and are trying to change the game.
SPEAKER_03So, whether it's through a startup or being climbing the corporate ladder, in being in these spaces to really change that narrative and to highlight and add these voices that have not been there for so long. Right now, we know it's it's a little hairy in the US, but I do think that people as a whole are starting to say, wait a minute, that doesn't make any sense. And the fact that we have these opportunities to create communities online and in person, and we can really start to lean in and cause these types of changes, that's what I'm very excited about.
SPEAKER_03And I think that we will see this for the better because new science will come out of this. There may be new things that we never even thought of, right? From new pathways or new therapies, right? Things along those lines that might really do a lot of things within pharma. Uh, but I'm also really excited to see the impact, the financial impact that can be had from these underserved communities that they have been overlooked for so long that now that we're putting a focus on them, look at what they've been able to do, right?
SPEAKER_03It's not that there isn't a financial uh opportunity there, but we can see that and we can actually track that over time. So those are things that I'm very excited about to see that diversity, although it is a very sticky subject right now, is really going to allow for us to really evolve as a society, I think, with thought, with science, and from a business perspective.
SPEAKER_00Excellent. We'll leave it there. But Dr. Denise Bronner, thank you so much. And it was a pleasure speaking with you today.
SPEAKER_03I know. Thanks for having me.
SPEAKER_00Hey, it's me again. I actually lied, that's not it. Denise also has a newsletter, and I wanted to give her a chance to talk about the pulse and why people might be interested in it.
SPEAKER_03The pulse is my LinkedIn newsletter. The reason why I did this newsletter is because I wanted to find a way to diagnose the health of clinical research in a new way and really talk about ways of prescribing treatments or initiatives to really help reach the true goal of health equity for all. So this newsletter really dives into opinion pieces and also just quick hits that only take you about four or five minutes to read to really be able to understand what is happening within pharma when we're talking about trying to achieve health equity.
SPEAKER_00This episode is sponsored by structured meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and, not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in teams? And the answer back then was, not really. Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own team's instance.
SPEAKER_00It changes teams just enough to check all the boxes for what's needed for great ad boards. And also, it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, we're back to the show.
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...